Granules India gets USFDA nod for Pot. chloride tablets

Granules India subsidiary Granules Pharmaceuticals Limited has received US Food and Drug Administration (FDA) approval for potassium chloride extended-release tablets.

530
USFDA Approval
USFDA Approval

Last Updated on October 17, 2024 by The Health Master

Granules India subsidiary Granules Pharmaceuticals Limited has received US Food and Drug Administration (FDA) approval for potassium chloride extended-release tablets.

The drug is bioequivalent of Klor-Con extended-release tablets of Upsher-Smith Laboratories, LLC.

Potassium chloride extended-release tablets is used for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium rich foods or diuretic dose reduction is insufficient.

According to IQVIA Health, Klor-Con brand and generic had US sales of approximately US$ 54 million MAT for the most recent twelve months ending in December 2019.

Granules has a total of 24 ANDA approvals from US FDA (22 Final approvals and 2 tentative approvals).

Also read: Granules India gets USFDA nod for Colchicine tablets

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news